Pharmacokinetics of Lenalidomide (Revlimid®) in Patients With Multiple Myeloma and Impaired Renal Function
The purpose of this study is to determine the pharmacokinetic profile of Revlimid® in patients presenting with Multiple Myeloma and impaired renal function, the safety of Revlimid® in the enrolled patients population.
and evaluate the efficacy of Revlimid®-Dexamethasone combination in patients presenting MM and impaired renal function at completion of 3 cycles of treatment.
|Study Design:||Endpoint Classification: Pharmacokinetics Study|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00779922
|Poitiers University Hospital|
|Poitiers, France, 86000|